

QUERY CONTROL FORM

RTIS USE ONLY

Application No. 10/007,197
Examiner-GAU webman-1617

Prepared by ACIark
Date 9/13/04
No. of queries 2

Tracking Number 0,000,250
Week Date 8/23/04

JACKET

a. Serial No.	f. Foreign Priority	k. Print Claim(s)	p. PTO-1449
b. Applicant(s)	g. Disclaimer	l. Print Fig.	q. PTOL-85b
c. Continuing Data	h. Microfiche Appendix	m. Searched Column	r. Abstract
d. PCT	i. Title	n. PTO-270/328	s. Sheets/Figs
e. Domestic Priority	j. Claims Allowed	o. PTO-892	t. Other

SPECIFICATION

a. Page Missing
b. Text Continuity
c. Holes through Data
d. Other Missing Text
e. Illegible Text
f. Duplicate Text
g. Brief Description
h. Sequence Listing
i. Appendix
j. Amendments
k. Other

① MESSAGE

Claims 4,9,10 & 14 are withdrawn and not rejoined per CUM 5/26/04

②

PTO-1449: Please either initial or line through citations. Copies provided for reference.

CLAIMS

a. Claim(s) Missing
b. Improper Dependency
c. Duplicate Numbers
d. Incorrect Numbering

e. Index Disagrees

f. Punctuation
g. Amendments
h. Bracketing
i. Missing Text
j. Duplicate Text
k. Other

Thank you
initials AC

RESPONSE

initials

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	Continuation of 09/661,836
		Filing Date	December 4, 2001
		First Named Inventor	James Ronald Lawter
		Group Art Unit	
		Examiner Name	
Sheet	2	of	4
		Attorney Docket Number	ORA 100/102 CON

U.S. PATENT
OFFICE
12/04/01

OTHER ART - NON PATENT LITERATURE DOCUMENTS		
Examiner's Initials ¹	Cite No. ²	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
	✓	BARKER, et al., "Oral care with vancomycin paste for reduction in incidence of alpha-hemolytic streptococcal sepsis," <i>J. Pediatr. Hematol. Oncol.</i> 17(2):151-55 (1995).
	✓	CARTEE, et al., "Evaluation of GM-CSF mouthwash for prevention of chemotherapy-induced mucositis: a randomized, double-blind, dose-ranging study," <i>Cytokines</i> 7(5):471-7 (1994).
	✓	CHI, et al., "Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients after cisplatin, fluorouracil, and leucovorin chemotherapy," <i>J. Clin. Oncol.</i> 13(10):2620-28 (1995).
		CUTLER & SCHUBERT, "Patient factors affecting <i>Helicobacter pylori</i> eradication with triple therapy," <i>American Journal of Gastroenterology</i> 88(4):505-509 (1993).
	✓	EPSTEIN & WONG, "The efficacy of sucralfate suspension in the prevention of oral mucositis due to radiation therapy," <i>Int. J. Radiat. Oncol. Biol. Phys.</i> 28(3):693-98 (1994).
	✓	EPSTEIN, et al., "Benzylamine hydrochloride in prevention and management of pain in oral mucositis associated with radiation therapy," <i>Oral Surg. Oral Med. Oral Pathol.</i> 62(2):145-8 (1986).
	✓	EPSTEIN, et al., "Prevention of oral mucositis in radiation therapy: a controlled study with benzylamine hydrochloride rinse," <i>Int. J. Radiation Oncology Biol. Phys.</i> 16(6):1571-5 (1989).
	✓	<i>Essentials of Medicinal Chemistry</i> John Wiley and Sons, Inc., pp 512-517 (1976).
		FACCHINI, et al., "Attività di fluoxapropene per uso topico nelle vaginiti aspecifiche. Confronto con metociclidina sollosalicilato," <i>Minerva Ginecologica</i> 41(12):609-614 (1989).
	✓	FERRETTI, et al., "Control of oral mucositis and candidiasis in marrow transplantation: a prospective, double-blind trial of chlorhexidine digluconate oral rinse," <i>Bone Marrow Transplant</i> 3(5):483-93 (1990).

Examiner's Signature	<i>[Signature]</i>	Date Considered	1/25/02
----------------------	--------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	Continuation of 09/661,836
		Filing Date	December 4, 2001
		First Named Inventor	James Ronald Lawter
		Group Art Unit	
		Examiner Name	
Sheet 3 of 4	Attorney Docket Number	ORA 100/102 CON	

OTHER ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	✓	FOOTE, et al., "Randomized trial of a chlorhexidine mouthwash for alleviation of radiation-induced mucositis," <i>J. Clin. Oncol.</i> 12(12):2830-33 (1994).	
		FRANCESCHI, et al., "Solitary J-pouch ulcer causing pouchitis-like syndrome," <i>Diseases of the Colon and Rectum</i> 28(8):515-517 (1986).	
	✓	LOPRINZI, et al., "Alleviation of cytotoxic therapy-induced normal tissue damage," <i>Sem. Oncol.</i> 22(2) Suppl. 3:95-97 (1995).	
	✓	MITSCHER, et al., "Quinolone antimicrobial agents. I. Versatile new synthesis of 1-alkyl-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids," <i>J. Med. Chem.</i> 21(5):485-9 (1978).	
		ROTHWELL & SPEKTOR, "Palliation of radiation-related mucositis," <i>Special Care in Dentistry</i> 10(1):21-25 (1990).	
		SCHENK, et al., "Controlled local delivery of tetracycline HCl in the treatment of perimplant mucosal hyperplasia and mucositis," <i>Clinical Oral Implants Research</i> 8(5):427-433 (1997).	
	✓	SONIS, 1993b, "Oral Complications in Cancer Therapy," in: <i>Principles and Practice of Oncology</i> , De Vita et al., eds., pp. 2385-2394 (J. B. Lippincott, Philadelphia).	
	J	<i>Special Care in Dentistry</i> Jan. Feb, pages 21-25 (1990).	
	✓	SPIJKERVET, et al., "Chlorhexidine inactivation by saliva," <i>Oral Surg. Oral Med. Oral Pathol.</i> 69(4):444-49 (1990).	
	J	VERDI, et al., "A double-blind, randomized, placebo-controlled, crossover trial of pentoxifylline for the prevention of chemotherapy-induced oral mucositis," <i>Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod.</i> 80(1):36-42 (1995).	

Examiner's Signature	<i>W. J. J. J.</i>	Date Considered	1/25/02
----------------------	--------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.